Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29705582 | 1.00 | DGAT1 (0.36) | DGAT1KLKB1 | |
| SCHEMBL27215183 | 0.86 | KLKB1 (0.33) | DGAT1KLKB1 | |
| SCHEMBL30592405 | 0.85 | MTNR1A (0.36) | DGAT1KLKB1 | |
| SCHEMBL3300284 | 0.83 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL27215111 | 0.82 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL1593371 | 0.82 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL27193468 | 0.81 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL27193478 | 0.80 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL24566116 | 0.80 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL24566903 | 0.80 | GSK3A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | PHARMARON UK LTD. (GB) | 2024-05-09 | — | — | US | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-103214480-B | Pyrazolopyridine alkynes benzene-like compounds and medicinal compositions thereof and application | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2015-12-16 | — | — | CN | disclosed |
| CN-103214480-A | Pyrazolopyridines alkynylbenzene compound and medicinal composition and application | GUANGZHOU INST BIOMED & HEALTH | 2013-07-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GSS, G6PC1 | DGAT1 206/4885KLKB1 713/4885 |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | DGAT1 565/4885KLKB1 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.